ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

Currency in EUR. All numbers in thousands
Total Revenue1,5304,6068,11813,983
Cost of Revenue----
Gross Profit1,5304,6068,11813,983
Operating Expenses
Research Development99,58966,02240,52819,698
Selling General and Administrative13,48211,5049,4156,274
Non Recurring----
Total Operating Expenses113,07177,52649,94325,972
Operating Income or Loss-111,541-72,920-41,825-11,989
Income from Continuing Operations
Total Other Income/Expenses Net-12,8334,1888,2511,649
Earnings Before Interest and Taxes-111,541-72,920-41,825-11,989
Interest Expense-97-5-6-16
Income Before Tax-124,374-68,732-33,574-10,340
Income Tax Expense-477-227-652-682
Minority Interest----
Net Income From Continuing Ops-123,897-68,505-32,922-9,658
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-123,897-68,505-32,922-9,658
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-123,897-68,505-32,922-9,658